Private Trust Company’s Sage Therapeutics SAGE Stock Holding History

Private Trust Company’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4	Closed	–	–	2359
2022 Q4	$0	Buy	+4	New	+$153	﹤0.01%	2257

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Private Trust Company's SAGE Position: Q1 2023 in Review

Private Trust Company sold out of Sage Therapeutics (SAGE) in Q1 2023, closing a stake of 4 shares.

Private Trust Company first reported a position in SAGE in Q4 2022 and held it in 1 quarter. The position peaked at $0 in Q4 2022. 213 funds tracked by Wall St. Rank hold SAGE as of Q1 2023.

Private Trust Company reported no remaining Sage Therapeutics position as of Q1 2023 after selling out during the quarter.
Private Trust Company sold 4 Sage Therapeutics shares in Q1 2023.
Private Trust Company first reported a position in Sage Therapeutics in Q4 2022 and held it in 1 quarter.
Private Trust Company's Sage Therapeutics position peaked at $0 in Q4 2022.
213 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2023.

Based on Private Trust Company's 13F filing for Q1 2023, filed 12 Apr 2023.